Drug Discount Programs Create More Cloud In Quest For Transparency
Behind a popular drug discount program are pharmacy benefits managers and even drug companies themselves, raising questions about whether such businesses may yet be another player in an opaque and complicated supply chain that is facilitating higher US drug prices, even as the most prominent company in the space, GoodRx, routinely criticizes soaring list prices.
You may also be interested in...
Commissioner’s comments were yet another sign that US FDA won’t clear a vaccine ahead of the election, but hours later the president suggests the White House may decline to clear the agency’s new guidance on emergency use authorization standards for COVID-19 vaccines, raising new concerns about political interference in any decisions.
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.
CARES Act appears to have overlooked Medicare coverage of a vaccine not granted traditional approval by US FDA. Meanwhile, other patient and provider vaccine reimbursement issues still need to be addressed by HHS and Congress to ensure widespread, affordable access to COVID-19 vaccines cleared by FDA under any pathway.